{"id":62531,"date":"2026-01-22T19:06:03","date_gmt":"2026-01-22T18:06:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/"},"modified":"2026-01-22T19:06:03","modified_gmt":"2026-01-22T18:06:03","slug":"bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/","title":{"rendered":"BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026"},"content":{"rendered":"
\n

ROCKVILLE, Md.–(BUSINESS WIRE)–BIOQUAL, Inc. (Pink Limited:BIOQ):<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
<\/td>\n\u00a0<\/td>\n\n

\nSix Months Ended<\/p>\n<\/td>\n

<\/td>\n\n

\nThree Months Ended<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\u00a0<\/td>\n\n

\nNovember 30,<\/p>\n<\/td>\n

<\/td>\n\n

\nNovember 30,<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\u00a0<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2025<\/span><\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2024<\/span><\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2025<\/span><\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2024<\/span><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nRevenue<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n20,834,840<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n23,165,920<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n10,979,441<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n11,395,438<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\u00a0<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nLoss Before Income Tax<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(532,917)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(2,604,227)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(189,485)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(1,672,402)<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\u00a0<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet Loss<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(386,117)<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n$<\/p>\n<\/td>\n

\n

\n(1,887,527)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(137,285)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(1,212,202)<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\u00a0<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nBasic Earnings per Share<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nof Common Stock<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(0.43)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(2.11)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(0.15)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(1.36)<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\u00a0<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nDiluted Earnings per Share<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nof Common Stock<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(0.43)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(2.11)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(0.15)<\/p>\n<\/td>\n

<\/td>\n\n

\n$<\/p>\n<\/td>\n

\n

\n(1.36)<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\u00a0<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nWeighted Average<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nNumber of Shares Outstanding<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nFor Basic Earnings Per Share<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,416<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,416<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,416<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,416<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\u00a0<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nWeighted Average<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nNumber of Shares Outstanding<\/p>\n<\/td>\n

\u00a0<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nFor Diluted Earnings Per Share<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n893,960<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,399<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n893,932<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n894,394<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nFor more detail related to the fiscal year 2026 unaudited second quarter results, please visit our web site at www.bioqual.com<\/a>.<\/p>\n

\nStatements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company\u2019s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company\u2019s ability to obtain new government and commercial contracts; continued demand for the use of animal models in scientific research; the Company\u2019s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company\u2019s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company\u2019s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing\/capital sources to the Company.<\/p>\n

Contacts<\/b> <\/p>\n

\nHanne E. Andersen, Ph.D., President and CSO, 240-404-7654<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ROCKVILLE, Md.–(BUSINESS WIRE)–BIOQUAL, Inc. (Pink Limited:BIOQ): \u00a0 \u00a0 Six Months Ended Three Months Ended \u00a0 \u00a0 November 30, November 30, \u00a0 \u00a0 \u00a0 2025 \u00a0 2024 \u00a0 2025 \u00a0 2024 \u00a0 Revenue \u00a0 $ 20,834,840 $ 23,165,920 $ 10,979,441 $ 11,395,438 \u00a0 \u00a0 \u00a0 Loss Before Income Tax \u00a0 $ (532,917) $ (2,604,227) $ (189,485) … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62531","6":"format-standard","7":"category-industry"},"yoast_head":"\nBIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md.–(BUSINESS WIRE)–BIOQUAL, Inc. (Pink Limited:BIOQ): \u00a0 \u00a0 Six Months Ended Three Months Ended \u00a0 \u00a0 November 30, November 30, \u00a0 \u00a0 \u00a0 2025 \u00a0 2024 \u00a0 2025 \u00a0 2024 \u00a0 Revenue \u00a0 $ 20,834,840 $ 23,165,920 $ 10,979,441 $ 11,395,438 \u00a0 \u00a0 \u00a0 Loss Before Income Tax \u00a0 $ (532,917) $ (2,604,227) $ (189,485) ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T18:06:03+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026\",\"datePublished\":\"2026-01-22T18:06:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\\\/\"},\"wordCount\":308,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\\\/\",\"name\":\"BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2026-01-22T18:06:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/","og_locale":"en_US","og_type":"article","og_title":"BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026 - Pharma Trend","og_description":"ROCKVILLE, Md.–(BUSINESS WIRE)–BIOQUAL, Inc. (Pink Limited:BIOQ): \u00a0 \u00a0 Six Months Ended Three Months Ended \u00a0 \u00a0 November 30, November 30, \u00a0 \u00a0 \u00a0 2025 \u00a0 2024 \u00a0 2025 \u00a0 2024 \u00a0 Revenue \u00a0 $ 20,834,840 $ 23,165,920 $ 10,979,441 $ 11,395,438 \u00a0 \u00a0 \u00a0 Loss Before Income Tax \u00a0 $ (532,917) $ (2,604,227) $ (189,485) ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-22T18:06:03+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026","datePublished":"2026-01-22T18:06:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/"},"wordCount":308,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/","url":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/","name":"BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2026-01-22T18:06:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bioqual-presents-unaudited-financial-results-for-second-quarter-of-fiscal-year-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62531"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62531\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}